Neuropsychiatric aspects of Huntington’s disease

J S Paulsen, R E Ready, J M Hamilton, M S Mega, J L Cummings

Abstract

Objective—Neuropsychiatric symptoms are common in Huntington’s disease and have been considered its presenting manifestation. Research characterising these symptoms in Huntington’s disease is variable, however, encumbered by limitations within and across studies. Gaining a better understanding of neuropsychiatric symptoms is essential, as these symptoms have implications for disease management, prognosis, and quality of life for patients and caregivers.

Method—Fifty two patients with Huntington’s disease were administered standardised measures of cognition, psychiatric symptoms, and motor abnormalities. Patient caregivers were administered the neuropsychiatric inventory.

Results—Ninety eight per cent of the patients exhibited neuropsychiatric symptoms, the most prevalent being dysphoria, agitation, irritability, apathy, and anxiety. Symptoms ranged from mild to severe and were unrelated to dementia and chorea.

Conclusions—Neuropsychiatric symptoms are prevalent in Huntington’s disease and are relatively independent of cognitive and motor aspects of the disease. Hypothesised links between neuropsychiatric symptoms of Huntington’s disease and frontal-striatal circuitry were explored. Findings indicate that dimensional measures of neuropsychiatric symptoms are essential to capture the full range of pathology in Huntington’s disease and are vital to include in a comprehensive assessment of the disease.

Keywords: Huntington’s disease; neuropsychiatry; dementia

Huntington’s disease is characterised by a triad of symptoms including motor disturbance, cognitive impairment, and psychiatric features. Although it is well established that psychiatric symptoms are common in Huntington’s disease research and clinical emphases have been on motor and cognitive aspects of the disorder. Reconsideration of the psychiatric manifestations of the disease is warranted. Firstly, psychiatric disturbances are most strongly associated with stress, disability, and placement decisions. Secondly, there is evidence that brain changes precede the traditional clinical diagnosis and psychiatric manifestations may predate motor signs by a decade. Finally, clinical trials are underway to slow Huntington’s disease progression in clinically affected patients with plans to treat “preclinical” patients imminent. Careful study of neuropsychiatric symptoms associated with Huntington’s disease is essential to help distinguish features that are pathognomonic from behaviours that are sensitive but not specific of the disease.

Models emphasising the role of the basal ganglia in neuropsychiatric disorders have been described over the past several decades. One recent overview suggests that because the earliest pathological changes in Huntington’s disease are in the associative portions of the striatum, the behaviours first affected by disease may be cognitive and psychiatric, rather than motor. Indeed, reviews of psychiatric symptoms in Huntington’s disease have suggested that depression, apathy, aggression, and disinhibition are common and suicide rates are over four times those of the general population. Previous studies have used an array of data collection methods, however, and standardised uniform assessment of psychiatric features in Huntington’s disease is lacking. The purpose of the current study is to use the well established neuropsychiatric inventory (NPI) to better characterise psychiatric symptoms in the disease.

Methods

SAMPLE

Participants were 52 consecutive patients with Huntington’s disease recruited from the Huntington’s Disease Clinical Research Program at the University of California at San Diego (n=29) and from the University of Iowa Huntington’s Disease Society of America Center of Excellence (n=23). The diagnosis was made by a senior staff neurologist based on the presence of an unequivocal movement disorder in a person with a family history of Huntington’s disease. All diagnoses were confirmed by DNA analysis for CAG expansion in the IT15 region of chromosome 4. All consecutive persons with an unequivocal diagnosis attending the UCSD Huntington’s disease clinic between 1994 and 1997 or attending the University of Iowa Huntington’s disease clinic between 1997 and 1999 were approached for inclusion in the study. No patient refused participation in the study. Four patients were excluded from the study for the following reasons: (a) having a medical illness other than Huntington’s disease (n=1); (b) having a history of head trauma with loss of consciousness (n=1); and (c) having an age of onset younger than 18 (n=2). Patients were 52% women with a mean age of 45.5 (SD 11.7) years (range 26–78) and a mean of 13.3 (SD 2.3) (range 6–17) years of education. Duration of disease (number of years since diagnosis) ranged from 0 to 20 years (mean 4.7 (SD 4.4)). Age of onset of illness ranged from

www.jnnp.com
25 to 57 with a mean of 43.1 (SD 9.6). There were no juvenile onset cases included in this study. Mini mental state examination \(^1\) (MMSE) scores ranged from 7 to 30 (mean 24.34 (SD 4.38), and Mattis dementia rating scale \(^2\) (DRS) scores ranged from 63 to 142 (mean 122 (SD 15.6)). Total chorea scores (assessed with the unified Huntington’s disease rating scale\(^3\) (UHDRS) ranged from 0 to 26 (assessed with the unified Huntington’s disease rating scale\(^4\) (UHDRS) ranged from 0 to 26 (mean 12.4 (SD 7.4)). Over 79% of patients were taking no medication (n=41). Four patients were taking a selective serotonin reuptake inhibitor (SSRI) and a typical neuroleptic drug, although dosages of the neuroleptic drug were very low in every case (<5 mg). One patient was taking an atypical neuroleptic drug. Four patients were taking SSRIs only and one patient was taking trazodone at bedtime for sleep. No patients were taking tetrabenazine. Analyses conducted with and without the subsample of patients taking psychotropic medications did not differ.

**PROCEDURE**

Huntington’s disease caregivers (n=52) were interviewed with the neuropsychiatric inventory\(^5\) (NPI) by JSP or a trained research assistant. The NPI assesses the frequency (four point rating scale) and severity (three point scale) of 10 neuropsychiatric disturbances (delusions, hallucinations, agitation, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviour), and a score from 0 to 12 was obtained for each scale by multiplying frequency by severity. An NPI total score was calculated by summing ratings for all symptoms. The NPI offers advantages over previous psychiatric research in Huntington’s disease; it is standardised, is not influenced by normal aging, it is used to characterise various neurological disorders,\(^2\)-\(^2\) and it is used as a measure of treatment response\(^5\) and in investigations of the biological correlates of neuropsychiatric symptoms. Informant reports of psychiatric symptoms in patients with neurodegenerative disease are commonly used and have been found to agree significantly with self reports.\(^2\)

Patients were administered the DRS and MMSE cognitive screening tests and the UHDRS as a measure of chorea severity. Scores on the MMSE were unavailable for two patients. After complete description of the study to the patients and caregivers as approved by the institutional review boards of both universities, informed consent was obtained.

Neuropsychiatric symptoms were not normally distributed. Therefore, all analyses used non-parametric tests. Specifically, Spearman correlation coefficients were used to examine associations between factors, and Mann-Whitney U tests were used for all comparisons of means. Due to the many analyses, a significance level of 0.01 was selected to control for multiple comparisons and to guard against type I errors.

**ASSOCIATIONS OF NPI WITH DEMOGRAPHIC AND DISEASE MEASURES**

The total NPI score was negatively correlated with years of education (r=−0.37). Mann-Whitney U tests comparing symptom means in male and female patients showed no significant differences. Age was negatively correlated with disinhibition (r=−0.41) and delusions (r=−0.36). Illness duration and chorea severity were not significantly associated with any NPI scores (table 1).

Neither measure of dementia severity (MMSE, DRS) was significantly correlated with neuropsychiatric symptoms (table 2). The DRS initiation and perseveration subscale showed a significant positive correlation with delusions (r=0.36). DRS attention was positively correlated with NPI aberrant motor behaviour (r=0.37) and dysphoria (r=0.41). DRS conceptualisation was positively correlated with aberrant motor behaviour (r=0.37). DRS supermarket verbal fluency was positively correlated with delusions (r=0.38).

**NEUROPSYCHIATRIC SYMPTOM INTERCORRELATIONS**

Intercorrelations with the NPI scale were investigated to assess associations among symptoms and to determine if symptom associations found in other neuropsychiatric populations were replicated. Nine significant symptom associations were found (table 3). The high correlation (r=0.81) between irritability and agitation suggests that these two scales are essentially measuring the same construct in this sample of patients with Huntington’s disease.

Three of the significant NPI symptom associations (agitation and irritability, anxiety and dysphoria, disinhibition, and irritability) were
Paulsen, Ready, Hamilton, et al

**p <0.01. †n=50; ‡n=52.

NPI=Neuropsychiatric inventory; DRS=Mattis dementia rating scale; MMSE=mini mental state examination; HD=Huntington’s disease.1–4

Huntington's disease.1–4

other estimates of psychiatric symptoms in NPI. Findings are consistent, however, with higher than that found in other dementias22 and patients exhibiting at least one symptom during this Huntington’s disease sample, with 98% of Neuropsychiatric symptoms were common in Discussion
disease (n=50) sample.22

Two significant associations from this sample (apathy and aberrant motor behaviour, dysphoria, and irritability) were not replicated. A significant association between anxiety and agitation found in a sample (n=22) of patients with progressive supranuclear palsy was replicated in the Huntington’s disease sample.

Discussion

Neuropsychiatric symptoms were common in this Huntington’s disease sample, with 98% of patients exhibiting at least one symptom during the previous month. This total incidence is higher than that found in other dementias and greater than previously reported in patients with other basal ganglia disorders also using the NPI. Findings are consistent, however, with other estimates of psychiatric symptoms in Huntington’s disease.-4

Dysphoria, agitation, irritability, apathy, or anxiety were present in over 50% of the sample, whereas psychotic symptoms (delusions and hallucinations) and aberrant motor behaviour were rare. Findings from this investigation are consistent with and enlarge past research on neuropsychiatric aspects of Huntington’s disease. Specifically, previous findings indicating that affective disorders and symptoms are common in Huntington’s disease were replicated. Apathy and irritability have similarly been found to be evident in about half of patients with Huntington’s disease.5

Given the input and output nuclei of the basal ganglia, it is not surprising that rates of neuropsychiatric symptoms are consistently high in Huntington’s disease. The dorsolateral-subcortical circuit projects from dorsal, anterior, and lateral regions of the prefrontal cortex via the dorsolateral head of the caudate, to the ventral anterior and medial dorsal nuclei of the thalamus, and plays a part in complex cognitive processes including working memory, generative behaviours, and the ability to establish and shift from one topic to another. Impairments in these so called “executive functions” also affect various aspects of emotional and behavioural control. For instance, regulatory functions of the circuit (generating and shifting) may alter the appropriate expression of frustration, resulting in apparent irritability and agitation.

| Table 2 Correlations between NPI neuropsychiatric symptoms and motor and cognitive measures for patients with HD |
| NPI Scale | Chorea | MMSE† | DRS‡ |
| Agitation | −0.02 | −0.09 | −0.11 | −0.15 | −0.13 | 0.02 | −0.10 | −0.01 |
| Dysphoria | −0.18 | 0.11 | 0.30 | 0.41** | 0.25 | 0.21 | 0.29 | −0.05 |
| Irritability | −0.14 | −0.09 | −0.08 | −0.23 | −0.18 | −0.08 | 0.01 | −0.00 |
| Anxiety | 0.11 | 0.06 | 0.09 | 0.13 | 0.11 | −0.01 | 0.06 | −0.03 |
| Apathy | −0.12 | −0.15 | −0.07 | 0.01 | −0.12 | −0.16 | 0.04 | −0.17 |
| Euphoria | 0.17 | −0.08 | 0.06 | −0.07 | −0.07 | 0.09 | 0.09 | 0.10 |
| Delusions | 0.05 | 0.01 | −0.10 | −0.24 | −0.23 | −0.09 | 0.04 | 0.04 |
| Aberrant motor | 0.12 | 0.09 | 0.24 | 0.37** | 0.37** | −0.15 | 0.18 | −0.01 |
| Hallucinations | −0.12 | 0.21 | 0.15 | 0.15 | 0.09 | 0.11 | 0.20 | −0.12 |
| NPI Total | −0.03 | 0.01 | 0.04 | 0.03 | −0.03 | −0.12 | 0.11 | −0.02 |

| Table 3 NPI neuropsychiatric symptom correlations in Huntington’s disease |
| NPI Scale | Agitation | Dysphoria | Irritability | Anxiety | Apathy | Euphoria | Delusions | Aberrant motor |
| Dysphoria | 0.26 | | | | | | | |
| Irritability | 0.81* | 0.20 | | | | | | |
| Anxiety | 0.41* | 0.40* | 0.43* | | | | | |
| Apathy | 0.09 | 0.14 | 0.14 | −0.05 | | | | |
| Euphoria | 0.31 | 0.10 | 0.25 | 0.25 | −0.08 | | | |
| Delusions | 0.38* | 0.22 | 0.37* | 0.34 | 0.08 | 0.30 | | |
| Aberrant motor | −0.01 | 0.31 | 0.07 | 0.28 | 0.34 | −0.05 | 0.02 | 0.40* |
| Hallucinations | −0.17 | 0.23 | 0.13 | 0.24 | 0.23 | −0.09 | 0.24 | 0.42* | 0.47* |

n=52.

NPI=Neuropsychiatric inventory.
*p <0.01.
part in response inhibition. Dysfunction of the medial circuit produces apathy, which has been shown to increase with illness duration in Huntington’s disease.2,3 These findings are consistent with the known degeneration in the disease, progressing from medial to lateral and from dorsal to ventral caudate, possibly impacting on the orbital and dorsolateral circuits before the cingulate circuit. Although apathy was noted in over 50% of patients with Huntington’s disease, Litvan et al. showed that patients with hypokinetic movement disorders were more likely to demonstrate hypoactive behaviours, such as apathy, whereas patients with hyperkinetic movement disorders (for example, Huntington’s disease) demonstrated relatively more hyperactive behaviours (agitation, irritability, and anxiety). This behavioural dissociation is consistent with circuitry involvement, suggesting hypoactive behaviours in persons with cingulate disruption and hyperactive behaviours in people with orbito/dorsal dysfunction.

Associations found between neuropsychiatric symptoms and demographic factors suggested that younger patients were more likely to experience psychotic symptoms and to be disinhibited. Although this finding is consistent with anecdotal reports, the pathophysiology of this association (age and psychosis) is unknown. It is possible that onset of Huntington’s disease at an earlier age disrupts frontostriatal circuitry that is not fully developed, resulting in variations in phenotype. Alternatively, other mediating factors likely exist to account for the variability in age of Huntington’s disease onset. It is possible that genetic factors influencing age at onset also impact on behavioural phenotype so that mechanisms influencing earlier onset also increase the probability of psychosis. Given that CAG repeat length accounts for only half of the variance in age of onset, additional research is needed to better understand Huntington’s disease phenotype and onset heterogeneity.

The increased breadth and dimensional assessment of neuropsychiatric symptoms provided by this study showed that patients with Huntington’s disease exhibited the full range of symptomatology, from mild to severe, as indicated by NPI frequency and severity ratings. Thus, assessment tools that rely on categorical diagnostic criteria to assess psychiatric aspects of Huntington’s disease would likely fail to detect the significant proportion of patients with subthreshold symptoms. Dimensional assessment tools, such as the NPI, may aid in the detection of mild or atypical cases of neuropsychiatric disorders and allow the capture of a full range of symptomatology. Neuropsychiatric assessment at varying degrees of severity also is important because these symptoms can be targeted for interventions and assessment can be used to track change over time during the natural course of the disease, or used to measure response to treatment.

Consistent with previous reports,2,3 few associations were found between neuropsychiatric symptoms and measures of cognitive or motor signs. Specifically, the MMSE, total DRS, chorea severity, and disease duration were not significantly correlated with any neuropsychiatric symptoms. These findings are consistent with other research2,29 and indicate that behavioural aspects of basal ganglia diseases are often independent of cognitive and motor symptoms, at least early in the disease.

Findings from this study have important implications for clinical neuropsychiatry. The current study suggests that nearly all patients with Huntington’s disease experience psychiatric symptoms. In addition, recent research as well as anecdotal evidence implies that psychiatric symptoms may be the first manifestation of disease in up to 79% of patients. It is likely, then, that clinical neuropsychiatrists may be among the professionals first and most often seen by persons with Huntington’s disease. Unfortunately, specific training for behavioural management of patients with Huntington’s disease is not typically available in general psychiatry and neurology programmes. Results of this study suggest that the infrequent patient with Huntington’s disease should be considered an opportunity for training and that psychiatric assessment should be a standard component of the Huntington’s disease evaluation. Excellent references for treatment can be found in Rosenblatt et al29 and Leroi and Michalon.30

This study was supported by National Institutes of Mental Health (NIMH) grants (5R20MH5331-05 and 1K02MH01579-01), a National Institutes of Neurological Disorders and Stroke grant (PO1410951-G), a Howard Hughes Medical Institute Pilot Grant, and a Carver Medical Research Initiative Grant Award to JSI, a National Institute on Aging (NIA) Alzheimer’s Disease Research Center grant, an Alzheimer’s Disease Research Center of California grant, and the Sidell-Kagen Foundation to JLG; a NIA grant to MSH (K08AG100784); a NIMH grant (R03MH59430-01) to JMH; and a NIH/NIA (T32AG006241) fellowship to RER.


www.jnnp.com


